Clinical trial NCT02443168: Radiolabeled Study of AG-221 in Healthy Male Subjects.
Official title: A Phase 1, Open-Label, Two-Part Study to Evaluate the Metabolism, Excretion, and Absolute Bioavailability of AG-221 in Healthy Adult Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Pharmacokinetic
Healthy
Male
AG-221
[14C]
Single dose
Oral
Intravenous
Lead sponsor: Celgene
Sponsor class: INDUSTRY
First posted: 2015-05-13
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This is a single-center, 2-part, open-label study to evaluate the metabolism and excretion and absolute bioavailability of \[14C\]-AG-221 in healthy male subjects. It is planned for 14 subjects to be enrolled; each subject will participate in a screening phase, a baseline phase, a treatment phase, and a follow up phone call. Blood, urine and fecal samples will be collected in Part 1 for analyses. Blood samples will be collected in Part 2. Subjects can only participate in either Part 1 or Part 2.

Detailed description: This will be a single-center, open-label, 2-part study in healthy adult males (n = 14). Parts 1 and 2 may be conducted in parallel.

Each subject will participate in a screening phase, a baseline phase, a treatment phase, and a follow up phone call. Subjects who have met all inclusion criteria and none of the exclusion criteria at screening will return to the clinical site on Day 1 for baseline assessments.

Part 1: Absorption, metabolism, and excretion (AME) Approximately 8 subjects will be enrolled in Part 1. Subjects will check into the clinic on the day before dosing. Following a 10 hour overnight fast, subjects will receive a single 100-mg dose of AG-221 solution containing a microtracer of \[14C\] AG 221 (\~ 300 nCi) under fasted conditions. The study drug will be administered as an oral solution with approximately 240 mL of room temperature, non-carbonated water.

Blood, urine, and fecal samples (and vomitus, if applicable) will be collected throughout the study for pharmacokinetic (PK), mass balance, and/or clinical laboratory assessments. Safety will be monitored throughout the study. Subjects will be discharged from the clinical site on Day 22 following completion of the required study procedures. Subjects will return to the unit on Day 29 for the last PK blood draw.

Urine and fecal samples will be collected each day until Day 22 (or the point of discharge if earlier) for measurement of total \[14C\] radioactivity. Blood samples for radioanalysis and PK assessment, inclusive of metabolite profiling/characterization, will be collected at pre-dose and at specified intervals through Day 29. Total \[14C\]-radioactivity in whole blood, plasma, urine, and feces (and vomitus, if applicable ) will be determined.

Part 2: Absolute bioavailability:

Approximately 6 subjects will be enrolled in Part 2. Qualified subjects who have met all inclusion criteria and none of the exclusion criteria at screening will return to the clinical site on Day 1, and will be housed at the clinical site from Day 1 until Day 3.

After an overnight fast of at least 10 hours, approximately 6 subjects will receive an oral dose (coated tablet) of 100 mg of AG-221 at Hour 0 on dosing day (Day 1). The study drug will be administered orally with approximately 240 mL of water. Four hours after the oral dose, the subjects will receive 100 micrograms AG-221 containing \~300 nCi of \[14C\]-AG-221administered as an intravenous bolus over approximately 2 minutes.

Subjects will be discharged from the unit upon completion of the 48 hour PK blood draw on Day 3. Subjects will return to the unit for additional PK blood draws on Days 5, 8, 11, 15, 18, 22, and 29.

No urine and fecal samples will be collected in Part 2.

Eligibility criteria: Inclusion Criteria:

1. Is a healthy adult male of any race and between 18 to 55 years of age, inclusive, at the time of signing the informed consent document.
2. Understands and voluntarily signs an informed consent document before any study related assessments/procedures are conducted.
3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
4. Must practice true abstinence1 or agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or a female of childbearing potential (FCBP)2 while participating in the study and for at least 28 days following the last dose of Investigational Product (IP), even if he has undergone a successful vasectomy.
5. Must have a Body Mass Index (BMI) between 18 and 33 kg/m2, inclusive, at screening.
6. Must be healthy as determined by the Investigator on the basis of medical history, physical examination (PE), clinical laboratory test results, vital signs, and 12-lead Electrocardiograms (ECG) at screening:

   * Must be afebrile (febrile is defined as ≥ 38.5°C or 101.3°F)
   * Supine systolic blood pressure (BP) must be in the range of 90 to 140 mmHg, supine diastolic BP must be in the range of 50 to 90 mmHg, and pulse rate must be in the range of 40 to 110 bpm
   * Normal or clinically acceptable 12-lead ECG, with a QT interval, corrected for heart rate using the Fridericia formula (QTcF) value ≤ 430 msec

Exclusion Criteria:

1. History of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
2. Any condition, including the presence of clinically significant (CS) laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study.
3. Any condition that confounds the ability to interpret data.
4. Exposed to an investigational drug (new chemical entity) within 30 days preceding dose administration, or five half-lives of that investigational drug, if known (whichever is longer).
5. Participation in more than one other radiolabeled investigational drug study within 12 months prior to check-in (Day -1).

   Note: The previous radiolabeled investigational drug must have been received more than 6 months prior to check-in (Day -1) and the total planned exposure from this current study and the previous study must be within the recommended levels considered safe, per US CFR governing Protection of Human Subjects; radioactive drugs for certain research uses.
6. Exposure to significant radiation (eg, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to check-in (Day -1).
7. Used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 30 days of dose administration.
8. Used any nonprescription systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of dose administration.
9. Used cytochrome P450 (CYP)3A inducers and/or inhibitors (including St. John's wort) within 30 days of dose administration. The Indiana University "Cytochrome P450 Drug Interaction Table" should be utilized to determine inhibitors and/or inducers of CYP3A.
10. Received a live vaccination within 90 days of dose administration.
11. Has any surgical or medical conditions possibly affecting ADME (Absorption, distribution, metabolism, and excretion), eg, bariatric procedure, or plans to have elective or medical procedures performed during the conduct of the trial.

    Prior appendectomy is acceptable, but prior cholecystectomy would result in exclusion from the study.
12. Donated blood or plasma within 8 weeks before dose administration to a blood bank or blood donation center.
13. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual \[DSM\]) within 2 years before dose administration, or positive drug screening test reflecting consumption of illicit drugs.
14. History of alcohol abuse within 2 years before dose administration, or positive alcohol screen.
15. Known to have serum hepatitis or known to be a carrier of HBsAg (Hepatitis B surface antigen) or HCV Ab (Hepatitis C viral antibody), or have a positive result to the test for HIV (Human immunodeficiency virus ) antibodies at screening.
16. Smokes more than 10 cigarettes per day, or the equivalent in other tobacco products.
17. Employed by the clinical site, or is related to an employee of the clinical site.
18. History of less than one bowel movements per day.

Primary outcomes:
measure: Pharmacokinetics - Total [14C] Whole blood and plasma
timeFrame: Approximately 3 weeks
measure: Pharmacokinetics - Total [14C] urine and feces
timeFrame: approximately 3 weeks
measure: Pharmacokinetics - Total [14C] Cumulative excretion
timeFrame: approximately 3 weeks
measure: Pharmacokinetics - Total [14C] radioactivity
timeFrame: approximately 4 weeks
measure: Pharmacokinetics - Total [14C] metabolites
timeFrame: approximately 3 weeks
measure: Pharmacokinetics: Metabolite profiling and characterization in select biological matrices (Part 1)
timeFrame: approximately 4 weeks
measure: Pharmacokinetics - Cmax
timeFrame: approximately 4 weeks
measure: Pharmacokinetics - AUC
timeFrame: approximately 4 weeks
measure: Pharmacokinetics - Tmax
timeFrame: approximately 4 weeks
measure: Pharmacokinetics -T1/2
timeFrame: approximately 4 weeks
Secondary outcomes:
measure: Adverse Events (AEs)
timeFrame: approximately 8 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Celgene Corporation
name: Edward O'Mara, MD
role: STUDY_DIRECTOR
References:
citation: Wang X, Chen J, Reyes J, Zhou S, Palmisano M, Li Y. A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach. Oncol Ther. 2020 Jun;8(1):91-102. doi: 10.1007/s40487-019-0097-7. Epub 2019 Jul 19.